[关键词]
[摘要]
脑卒中在全球范围内是第2大致死以及主要致残性疾病,而在中国其已超过心血管疾病成为第1致死因素。因此,防治脑卒中,尤其是缺血性脑卒中显得尤为重要。目前,缺血性脑卒中治疗药物除唯一证明有效的静脉溶栓药组织纤维蛋白溶酶原激活剂(tPA)外,其他尚缺乏循证医学证据或疗效不确定。而近年来中医药治疗缺血性脑卒中引起广泛关注,通心络胶囊是其中研究较多的代表药物之一。从血管保护和神经保护2方面,就通心络胶囊治疗缺血性脑卒中的作用机制进行总结。
[Key word]
[Abstract]
Globally, stroke is the second leading cause of death and a major global disability. In China, it has exceeded heart disease to become the leading cause of death. Thus, it is urgent to prevent and treat stroke, particularly ischemic stroke. At present, except the tissue plasminogen activator (tPA) only therapy for ischemic stroke with proven efficacy, the others still lack evidence of evidence-based medicine or their curative effects are insufficient. However, in recent years, Chinese medicine, such as Tongxinluo Capsule, in treatment of ischemic stroke has attracted extensive attention. This article reviewed the research progress in mechanisms of Tongxinluo Capsule in treatment of ischemic stroke from two aspects:vascular protection and neuroprotection.
[中图分类号]
[基金项目]
国家重点基础研究发展计划(“973”计划)(2012CB518606)